Sorfequiline Shows Promise in Shortening TB Treatment
Sorfequiline, previously referred to as TBAJ-876, was evaluated in combination with pretomanid and linezolid in a well-structured clinical trial targeting patients with drug-sensitive TB.
Recent trial results presented at an international conference on lung health unveiled that sorfequiline, a next-generation antibiotic, combined with pretomanid and linezolid in what's called the "SPaL" regimen, has demonstrated significant potential to enhance tuberculosis (TB) treatment.
The pan-Phase 2 clinical trial indicated that sorfequiline outperformed bedaquiline. The 100 mg SPaL regimen showed superior efficacy against TB compared to standard treatments, suggesting it could notably reduce the treatment duration for active TB infections. Additionally, the SPaL regimen maintained a safety profile comparable to established treatments for patients with drug-sensitive TB.
Conducted across multiple sites in different countries, the trial spearheaded by TB Alliance has broad implications for global health, aiming to advance the fight against TB. Dr. Mel Spigelman, President and CEO, emphasized that the advancements in TB treatments are essential benefits for healthcare systems and communities affected by TB.
Both sorfequiline and bedaquiline belong to the diarylquinoline class of antibiotics, which effectively target a crucial enzyme responsible for the energy production of tuberculosis bacteria. Bedaquiline was a groundbreaking approval in 2012 for drug-resistant TB treatment, marking significant progress in antibiotic development. However, the emergence of bedaquiline-resistant TB strains necessitates newer solutions.
TB Alliance's ongoing commitment to the development of sorfequiline from initial phases to late-stage clinical trials speaks volumes about their dedication to innovative treatments. Recent studies suggest sorfequiline could possess a superior safety profile over its counterpart, bedaquiline, and show effectiveness against strains that have developed resistance.
Dr. Rod Dawson, Principal Investigator for the trial, expressed optimism that the ongoing research continues to promise shorter and safer treatment options for the millions impacted by TB. He acknowledges the ambitious goals of eradicating TB as more feasible due to these advancements.
Looking forward, TB Alliance plans to reinforce collaborations with high-burden countries like India and South Africa, anticipating a Phase 3 clinical trial in the near future. This phase aims to potentially approve a new drug and treatment regimen, marking a significant step towards achieving ultra-short regimens for TB.
A participant in the NC-009 trial, Thuto Pulane, shared a positive view of the treatment experience, expressing encouragement for others who may be hesitant about TB treatments. The feedback highlights a growing sense of hope in the fight against TB.
Sorfequiline is being developed as a pill, with the SPaL regimen aiming for an all-oral treatment approach. Furthermore, TB Alliance is exploring innovative drug delivery methods, including a long-acting injectable (LAI), which could potentially reduce treatment times significantly, down to as little as one month.
Dr. Maria Beumont, Vice President and Chief Medical Officer at TB Alliance, asserted that the longstanding six-month standard treatment duration for TB could be significantly shortened. The promising results of the trial are steps towards this goal, reinforcing the vision of making TB a manageable health issue globally.
Understanding Tuberculosis
TB remains a challenging infection to eradicate, demanding a combination of medications for multiple months. Even once symptoms alleviate, continued medication is necessary to ensure complete eradication of the disease. This persistent prevalence is exacerbated by outdated treatment options. Therefore, the need for innovative drug regimens to combat the TB pandemic effectively is paramount.
The BPaL regimen, comprising bedaquiline, pretomanid, and linezolid, was initially studied by TB Alliance leading to its first regulatory approval in 2019 targeted at highly drug-resistant TB strains. This marked a significant milestone in TB treatment history, where previously treatment for drug-resistant TB was limited and often not successful. Following the approval, tens of thousands of treatment courses have been requested globally, reflecting a move towards better therapeutic outcomes.
In earlier studies, sorfequiline displayed anti-mycobacterial activity significantly exceeding that of bedaquiline. Its safety profile is under continuous examination, with initial trials showing minimal adverse effects among the participants.
About TB Alliance
TB Alliance is a non-profit organization committed to developing faster-acting, affordable drug regimens. With global partnerships, their mission is to ensure equitable access to better TB treatments, improving health outcomes worldwide. They operate with support from various international health organizations focused on eradicating TB.
Media contact:
Jess Wiggs at [email protected], +1-240-425-7117
Lynda Mwakisha at [email protected], +254-704-589-177
